Quest Diagnostics Launches Zika Antibody Test Created by CDC
Monday, September 26, 2016
Quest Diagnostics announced a new antibody test service — based on the Zika immunoglobulin M antibody capture enzyme-linked immunosorbent assay developed by the CDC — is available for the detection of infection associated with Zika virus, according to a news release.
The CDC licensed the test to Quest Diagnostics and other national reference laboratories to help combat Zika in the United States. Quest will offer access to Zika virus antibody and molecular laboratory test services through 2,300 service centers for people in the U.S., Puerto Rico and other U.S. territories.
“Quest now provides physicians and patients with access to a robust, complementary range of Zika test options for aiding diagnosis of Zika infection,” Rick L. Pesano, MD, PhD, Quest’s vice president of research and development, said in the release. “Quest’s national scale, diagnostic expertise and relationships with half the country’s physicians may be an increasingly important complement to public health response should the number of suspected Zika cases and demand for testing grow in the United States.”
- Health Care